Free Trial

Marker Therapeutics 3/31/2025 Earnings Report

Marker Therapeutics logo
$1.07 +0.02 (+1.90%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Marker Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Marker Therapeutics Revenue Results

Actual Revenue
$1.22 million
Expected Revenue
$5.25 million
Beat/Miss
Missed by -$4.03 million
YoY Revenue Growth
N/A

Marker Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Marker Therapeutics' next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

Remove Ads

Marker Therapeutics Earnings Headlines

Brookline Capital Management Forecasts MRKR Q1 Earnings
Brookline Capital Management Estimates MRKR FY2026 Earnings
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

View Marker Therapeutics Profile

More Earnings Resources from MarketBeat